Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Adagene Inc. ADAG
$1.38
-$0.06 (-4.17%)
На 18:04, 12 мая 2023
Ключевые показатели
-
Marketcap
57784341.00000000
-
week52high
3.41
-
week52low
0.90
-
Revenue
9292724
-
P/E TTM
-1
-
Beta
0.05137100
-
EPS
-1.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 мар 2023 г. в 21:25
Описание компании
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 01 февр 2022 г. |
| Morgan Stanley | Overweight | Overweight | 06 янв 2022 г. |
| Morgan Stanley | Overweight | Overweight | 16 июл 2021 г. |
| China Renaissance | Buy | 25 июн 2021 г. | |
| Morgan Stanley | Overweight | 08 мар 2021 г. | |
| Morgan Stanley | Overweight | Overweight | 09 сент 2022 г. |
| HC Wainwright & Co. | Buy | 07 дек 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
GlobeNewsWire
05 янв 2023 г. в 16:01
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene's Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference.
Adagene to Participate in Investor Conferences in May and June
GlobeNewsWire
12 мая 2022 г. в 07:00
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company's management will participate in the following upcoming investor conferences:
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
Zacks Investment Research
17 мар 2022 г. в 12:02
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Benzinga
16 мар 2022 г. в 10:07
The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will.
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
GuruFocus
10 мар 2022 г. в 17:30
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.